Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging
Introduction: OS2966 is a first-in-class, humanized and de-immunized monoclonal antibody which targets the adhesion receptor subunit, CD29/β1 integrin. CD29 expression is highly upregulated in glioblastoma and has been shown to drive tumor progression, invasion, and resistance to multiple modalities...
Saved in:
Main Authors: | Chibueze D. Nwagwu (Author), Amanda V. Immidisetti (Author), Gabriela Bukanowska (Author), Michael A. Vogelbaum (Author), Anne-Marie Carbonell (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Convection Enhanced Delivery in the Setting of High-Grade Gliomas
by: Chibueze D. Nwagwu, et al.
Published: (2021) -
Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience
by: Pavan S. Upadhyayula, et al.
Published: (2020) -
Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience
by: Umberto Tosi, et al.
Published: (2020) -
Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
by: Hitoshi Terui, et al.
Published: (2023) -
In situ antibody phage display yields optimal inhibitors of integrin α11/β1
by: Eugenio Gallo, et al.
Published: (2020)